Specifically, molecular targeted therapeutic drugs, such as inhibitors of VEGF, EGFR, and HER2, play a pivotal role in the management of malignant tumors, with their effectiveness being closely tied to the composition of the intestinal microbiota (Huang et al. 2019). The gene discussed is VEGFA; the disease is cancer.